Navigation Links
Rigel to Webcast Investor Update on October 27, 2008
Date:10/21/2008

SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will webcast its investor update, in conjunction with the American College of Rheumatology Meeting (ACR), on October 27, 2008 from 2:00-3:00pm Pacific Time. Members of Rigel's senior management team will provide an update on the company's lead product candidate, R788, a novel, oral Syk kinase inhibitor. R788 is currently being evaluated in two Phase 2b clinical trials in patients with rheumatoid arthritis, as well as Phase 2 clinical trials in immune thrombocytopenic purpura and B-cell lymphomas.

The event will be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary. The webcast will be archived and available for replay on the Company's website.

In addition, Rigel will be participating in both a plenary session and a poster session during ACR in San Francisco, California from October 24-29, 2008.

ACR Presentation Details

Plenary session: Monday, Oct 27, 12:15-12:30 PM

Session: Discovery 2008: Pathogenesis and Treatment of Inflammatory

Arthritis

Title: 1189 - Treatment of Rheumatoid Arthritis (RA) with a Syk Kinase

Inhibitor: A 12-week randomized placebo controlled study

Location: Hall C

Poster session: Tuesday, Oct 28, 9:00-11:00 AM

Session: Biology and Pathology of Bone and Cartilage

Title: 1293 - R406, a Small Molecule Syk inhibitor, Suppresses Osteoclast

Differentiation of Murine Bone Mar
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Rigel Announces Third Quarter 2007 Financial Results
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
3. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
4. Rigel Announces Offering of 4,000,000 Shares of Common Stock
5. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
6. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
7. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
8. Rigel Announces First Quarter 2008 Financial Results
9. Rigel to Present at Collins Stewart Growth Conference
10. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
11. Webcast Alert: Kaiser Permanente Residency Program Open House
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... HealthDay Reporter , MONDAY, July 28, 2014 (HealthDay ... may be able to take hormone replacement therapy soon after ... to a new study. Previous studies, including the large-scale ... effects on the heart. But, many of those women were ... past menopause. In this new study, researchers wanted ...
(Date:7/29/2014)... Kelly and Zhi Sheng , assistant professors ... recently received a grant from the Commonwealth Health ... effort that may lead to new treatment approaches. , ... , The grant will fund a two-year project to ... the BRCA1 gene. This type of cancer often has ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The global ... 9,542.3 million by 2020, growing at an estimated CAGR ... new study by Grand View Research, Inc. Introduction of ... devices by the geriatric population, along with increase in ... the major drivers of this market. In addition, presence ...
(Date:7/29/2014)... July 29, 2014 On Friday, the ... declaring the week of October 12-18, 2014, as "National ... management in improving healthcare outcomes for patients. The resolution ... John Boozman (R-AR), with support by the Case Management ... to honor case management professionals for their contributions to ...
(Date:7/29/2014)... “Our years of experience with ... to insulate their homes properly simply due to ... heat transfer and conduction,” Clean Crawls says in ... released an article explaining exactly how heat ... bills. , To contact Clean Crawls for their ...
Breaking Medicine News(10 mins):Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3Health News:Scientists to study hereditary breast cancer to find BRCA1 treatment 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2
... men generally have lower prostate specific antigen levels than men ... the PSA test may not be as good at identifying ... 2,800 men with no evidence of prostate cancer. Results showed ... across all age groups and throughout all races. A study ...
... is effective in reducing the risk of death following a ... attack // find researchers according to latest research. ,In ... reviparin on the composite outcome of death, heart attack, and ... was reduced from 11 percent of patients in the placebo ...
... broiled fish, such as tuna, may lower stroke risk ... adults 65 and older. Study participants answered food-frequency questionnaires ... years. ,Results showed 626 of the participants experienced ... broiled or baked fish one- to four-times per week ...
... with a long-acting beta2-agonist (formoterol) can actually provide significant ... high doses of inhaled steroid, say researchers according to ... of various combinations of medicine on asthma symptoms in ... were analyzed. The patients were divided into three treatment ...
... over whether hormone replacement therapy is safe and effective ... the pros and cons of this controversial therapy. ... five years. All the women studied were 50 years ... others did not.Results showed women free of menopausal symptoms ...
... The use of alternative or complementary therapies have increased ... people using // at least one form of alternative ... biofeedback, yoga, hypnosis, acupuncture, chiropractic care, and high-dose vitamins. ... their own survey taken in 1997 to the National ...
Cached Medicine News:
(Date:7/29/2014)... , July 29, 2014 Today, Frost ... Frost & Sullivan Best Practices Award for Customer ... a cloud-based platform that connects digital health application ... as providers, pharmaceutical companies, prevention and wellness companies, ... Each year, Frost & Sullivan presents ...
(Date:7/29/2014)...   , First patient begins treatment ... safety of MSB0010718C in patients with metastatic Merkel cell carcinoma ... cancer lacking effective treatments   MSB0010718C is also currently ... for the treatment of solid tumors that aims to recruit ... of Merck KGaA, Darmstadt, Germany , today ...
(Date:7/28/2014)... (NASDAQ: LMNX ) today announced financial results ... and operating highlights include the following: , ... percent increase over the second quarter of 2013. ... 9 percent increase over the second quarter of 2013.  ... which included 148 LX systems, 96 MAGPIX systems, and ...
Breaking Medicine Technology:Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17
... Reportlinker.com announces that a new market research ... Cancer Pain Therapeutics - ... http://www.reportlinker.com/p0546769/Cancer-Pain-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Assessment and Market Forecasts to 2017 ...
... YORK, June 1, 2011 ... market research report is available ... Interventional Neurology - ... and Market Forecasts to 2017 ...
Cached Medicine Technology:Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12
... order tips. Each box contains 10,000 tips ... in easy-to-open, re-sealable Bulk Packs of 200 ... with a tamper-proof strip which can easily ... Diamond Tips. Bulk Packs are closed using ...
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
... Theken eDISC is a revolutionary advancement in ... assess and manage their patients. The eDISC's ... the eDISC from 1st and 2nd generation ... loads of the lumbar spine, the eDISC ...
Medicine Products: